Investment Banking

The Quarterly Rx: Q2 2022 U.S. Biopharma Recap

An increase in M&A and financing activity to end biopharma's Q2 have rekindled hope that we’re finally out of the biotech winter, while others fear it’s just a false spring. As companies continue to weather the storm, the focus remains on cash runway, quality news flow/clinical data, and consolidation. William Blair's Biopharma team shares perspectives in The Quarterly Rx: Q2 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

More News and Insights

The Brink’s Company: Initiation of Research Coverage

William Blair initiated research coverage of The Brink’s Company (BCO $97.00), a logistics-based cash and valuables management company that spans across more than 100 countries, with solutions for cash-in-transit, ATM services, cash management services, vault outsourcing, money processing, and transportation of high-value goods.

Read more

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit